Day: September 18, 2024

HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 18.9.2024 AT 14:00 In 2025, Huhtamaki will publish financial information as follows:Results 2024 February 14Annual report 2024 Week commencing March 10Interim report, January 1-March 31,2025 April 24Half-yearly report, January 1-June 30, 2025 July 24Interim report, January 1-September 30, 2025 October 23Huhtamaki observes a silent period prior to the publication of financial information. The silent period before publication of the 2024 Results is four weeks. The silent period before publication of the half-yearly report and interim reports starts on the last day of the reporting period in question. Huhtamäki Oyj’s Annual General Meeting (AGM) is planned to be held on Thursday, April 24, 2025. The Board of Directors will summon the AGM at a later date. A shareholder may request...

HONKARAKENNE OYJ Stock Exchange Release 18 September 2024 at 14:00 HONKARAKENNE OYJ – MANAGERS’ TRANSACTIONS Honkarakenne Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Eino Hekali Position: Other senior manager Issuer: Honkarakenne OyjLEI: 7437007POZXRBIWNJ629Notification type: INITIAL NOTIFICATIONReference number: 77779/4/6____________________________________________Transaction date: 2024-08-23Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHAREISIN: FI0009900104Nature of transaction: ACQUISITION Transaction details(1): Volume: 204 Unit price: 2.9 EUR Aggregated transactions (1): Volume: 204 Volume weighted average price: 2.9 EUR ____________________________________________Transaction date: 2024-08-27Venue: NASDAQ HELSINKI LTD (XHEL)...

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the launch of its new corporate brand. Oxford Biomedica is rebranding as OXB, unveiling a more modern and recognisable visual identity that reinforces its transformation into a global pure-play cell and gene therapy CDMO. The new identity reflects OXB’s unique combination of technical excellence, innovation and unwavering commitment to deliver consistent high quality at every stage of viral vector development and manufacturing. The new branding represents the agile execution and creativity that enable OXB to deliver on clients’ goals, while also conveying accountability, professionalism and teamwork – core values...

Nordecon AS, together with its subsidiary Eurocon Ukraine TOV as joint bidders, and the Estonian Centre for International Development (ESTDEV) have signed a construction contract for the reconstruction of a building into an apartment complex for internally displaced persons in Ovruch, Zhytomyr Oblast, Ukraine. The contract value is 1.8 million euros, plus VAT, and the construction period is 275 days. Nordecon (www.nordecon.com) is a group of construction companies whose core business is construction project management and general contracting in the buildings and infrastructures segment. Geographically the Group operates in Estonia, Ukraine and Sweden. The parent of the Group is Nordecon AS, a company registered and located in Tallinn, Estonia. The consolidated revenue of the Group in 2023 was 278 million euros. Currently Nordecon Group...

VANCOUVER, British Columbia, Sept. 18, 2024 (GLOBE NEWSWIRE) — Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce that it has acquired by low-cost staking ten new prospective uranium exploration dispositions (or “claims”). The new claims will make up the Company’s Stone Island Project, covering 9,993 hectares and further bolstering Stallion’s land package in the prolific Southwestern Athabasca Basin. The new dispositions are contiguous to the Western Athabasca Basin JV Project (Stallion and Atha Energy) and are 100% owned by Stallion Uranium. Key Exploration HighlightsStaked 9,993 ha of contiguous claims New dispositions host the extension of Stallion’s Coyote Corridor Shallow depth to Unconformity of 100-400m Hosts the extensions of known...

Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20 treatment can successfully eliminate initial BRIUMVI infusion NEW YORK, Sept. 18, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Highlights from the presentation are outlined below. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “We are excited to present an update from our ENHANCE Phase 3b study which is evaluating potential optimized dosing...